The effects of bone remodeling inhibition by alendronate on three-dimensional microarchitecture of subchondral bone tissues in guinea pig primary osteoarthrosis.
We assessed whether increase of subchondral bone density enhances cartilage stress during impact loading, leading to progressive cartilage degeneration and accelerated osteoarthrosis (OA) progression. Sixty-six male guinea pigs were randomly divided into six groups. During a 9-week treatment period, four groups received twice-weekly subcutaneous injections of alendronate (ALN) in two doses: two groups received 10 microg/kg and two groups received 50 microg/kg. The two control groups received vehicle. After 9 weeks, one 10 microg/kg ALN group, one 50 microg/kg ALN group, and one control group were killed. The remaining three groups (17-week groups) were left for an additional 8 weeks, receiving the same treatment regimen before death. The left proximal tibiae were scanned by micro-computed tomography to quantify the microarchitecture of subchondral bone, followed by mechanical testing and determination of collagen and mineral. The control groups had typical OA-related cartilage degeneration at 9 and 17 weeks, whereas the 50 microg/kg ALN group had even worse degeneration in the medial condyle. It is unclear whether there is a direct or a secondary effect of ALN on the cartilage. The 9-week ALN group had significantly greater subchondral plate thickness. The 9- and 17-week groups had similar changes of cancellous bone microarchitecture, with greater volume fraction and connectivity and an extremely plate-like structure. The 9-week ALN group had greater bone mineral concentration, and the 17-week ALN group had reduced collagen concentration and greater mineral concentration. Treatment with ALN did not significantly change the mechanical properties of the cancellous bone.
Ding
Ming
M
Orthopedic Research Laboratory, Department of Orthopedics, Aarhus University Hospital, Aarhus, Denmark. ming.ding@ouh.regionsyddanmark.dk
Danielsen
Carl Christian
CC
Hvid
Ivan
I
D019386:Alendronate / Q000494:pharmacology*; D000818:Animals; D015519:Bone Density / Q000187:drug effects / Q000502:physiology; D050071:Bone Density Conservation Agents / Q000494:pharmacology; D016723:Bone Remodeling / Q000187:drug effects* / Q000502:physiology; D001842:Bone and Bones / Q000187:drug effects* / Q000473:pathology / Q000503:physiopathology; D002358:Cartilage, Articular / Q000187:drug effects* / Q000473:pathology / Q000503:physiopathology; D003094:Collagen / Q000187:drug effects / Q000378:metabolism; D004195:Disease Models, Animal; D018450:Disease Progression; D004334:Drug Administration Schedule; D006168:Guinea Pigs; D007596:Joints / Q000187:drug effects / Q000473:pathology / Q000503:physiopathology; D007719:Knee Joint / Q000187:drug effects / Q000473:pathology / Q000503:physiopathology; D008297:Male; D010003:Osteoarthritis / Q000139:chemically induced* / Q000473:pathology / Q000503:physiopathology; D013314:Stress, Mechanical; D013977:Tibia / Q000187:drug effects / Q000473:pathology / Q000503:physiopathology; D016474:Weight-Bearing / Q000502:physiology
D050071:Bone Density Conservation Agents; D003094:Collagen; D019386:Alendronate